Anzeige
Mehr »
Login
Dienstag, 30.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
18 Leser
Artikel bewerten:
(0)

Analysis of the European Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations

DUBLIN, June 25, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/khpzsv/2015_market) has announced the addition of the "2015 Market Segmentation Analysis of the European Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
A new study of the major business opportunities emerging in the European cancer diagnostics market during the nextfive years.

The report examines trends in the European market; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the European cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field.

Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

European Market Overview

- Five-year test volume and sales projections by country.
- Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country.
- Estimated universe of laboratories performing cancer diagnostic testing by country.
- Cancer statistics, etiology and recent developments in Europe.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.
- Design criteria for new products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.

Supplier Shares, Sales and Volume Forecasts

- Sales and market shares of major cancer diagnostic product

suppliers by individual test and country.

- Five-year test volume and sales forecasts for major tumor markers by country and market segment, including:
- Hospitals
- Commercial/Private Laboratories
- Physician Offices/Group Practices

Instrumentation Review

- Analysis of major molecular diagnostic and immunodignostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

- Assessment of latest technologies and their potential applications for cancer diagnostic testing.
- Review of competing/complementing technologies.
- Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

- Strategic assessments ofmajor suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Companies Mentioned

- Abbott
- AdnaGen
- Agilent Technologies
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CellSearch
- Diagnocure
- DiaSorin
- Eiken Chemical
- Elitech Group
- Epigenomics
- Enterix
- Enzo Biochem
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic/Gen-Probe
- OncoLab
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Thermo Fisher
- Tosoh
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zilla

For more information visit http://www.researchandmarkets.com/research/khpzsv/2015_market


Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.